Achieve Life Sciences (ACHV) Other Non-Current Liabilities (2010 - 2026)

Achieve Life Sciences has disclosed Other Non-Current Liabilities across 12 years of filings, most recently posting $1.3 million for Q1 2026.

• Quarterly Other Non-Current Liabilities rose 2.58% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (up 2.58% YoY) and the FY2025 annual result came in at $1.6 million, up 35.51% from the prior year.
• Other Non-Current Liabilities fell to $1.3 million in Q1 2026, from $1.6 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $16.7 million in Q4 2023 and troughed at $580000.0 in Q1 2024.
• A 4-year average of $3.0 million and a median of $1.2 million in 2024 frame the typical range for Other Non-Current Liabilities.
• Annual changes were most pronounced in 2024 — Other Non-Current Liabilities sank 93.1% — and 2025, when it jumped 113.79%.
• Tracing ACHV's Other Non-Current Liabilities over 4 years: stood at $16.7 million in 2023, then plunged by 93.1% to $1.1 million in 2024, then jumped by 35.51% to $1.6 million in 2025, then declined by 18.3% to $1.3 million in 2026.
• Business Quant data shows ACHV's Other Non-Current Liabilities at $1.3 million in Q1 2026, $1.6 million in Q4 2025, and $1.2 million in Q1 2025.